Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder

Psychoneuroendocrinology

Volumn 65, Issue , 2016, Pages 76-83

  Bond, David J ^a,b   Andreazza, Ana C ^c   Hughes, John ^d   Dhanoa, Taj ^a   Torres, Ivan J ^a   Kozicky, Jan Marie ^a   Young, L Trevor ^c   Lam, Raymond W ^a   Yatham, Lakshmi N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bipolar disorder; Body mass index; Cytokines; Inflammation; Obesity; Relapse

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIPOLAR I DISORDER; BODY MASS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MANIA; MOOD DISORDER; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; RELAPSE; AFFECT; BIPOLAR DISORDER; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY; RECURRENT DISEASE; YOUNG ADULT;

AFFECT; BIPOLAR DISORDER; BODY MASS INDEX; CASE-CONTROL STUDIES; CYTOKINES; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFLAMMATION; MALE; OBESITY; RECURRENCE; YOUNG ADULT;

EID: 84958177917     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.12.012     Document Type: Article

References (49)

1. Aschbacher K., Epel E., Wolkowitz O.M., Prather A.A., Puterman E., Dhabhar F.S. Maintenance of a positive outlook during acute stress protects against pro-inflammatory reactivity and future depressive symptoms. Brain Behav. Immun. 2012, 26:346-352.
2. Astrup A.S., Tarnow L., Pietraszek L., Schalkwijk C.G., Stehouwer C.D., Parving H.H., Rossing P. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008, 31:1170-1176.
3. Ayorech Z., Tracy D.K., Baumeister D., Giaroli G. Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J. Affect. Disord. 2015, 174:467-478.
4. Banks W.A., Farr S.A., La Scola M.E., Morley J.E. Intravenous human interleukin-1alpha impairs memory processing in mice: dependence on blood-brain barrier transport into posterior division of the septum. J Pharmacol. Exp. Ther. 2001, 299:536-541.
5. Barbosa I.G., Rocha N.P., de Miranda A.S., Magalhaes P.V., Huguet R.B., de Souza L.P., Kapczinski F., Teixeira A.L. Increased levels of adipokines in bipolar disorder. J. Psychiatr. Res. 2012, 46:389-393.
6. Bond D.J., Kauer-Sant'Anna M., Lam R.W., Yatham L.N. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). J. Affect. Disord. 2010, 124:108-117.
7. Bond D.J., Lang D.J., Noronha M.M., Kunz M., Torres I.J., Su W., Honer W.G., Lam R.W., Yatham L.N. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol. Psychiatry 2011, 70:381-387.
8. Bond D.J., Ha T.H., Lang D.J., Su W., Torres I.J., Honer W.G., Lam R.W., Yatham L.N. Body mass index-related regional gray and white matter volume reductions in first-episode mania patients. Biol. Psychiatry 2014, 76:138-145.
9. Bond D.J., da Silveira L.E., MacMillan E.L., Torres I.J., Lang D.J., Su W., Honer W.G., Lam R.W., Yatham L.N. Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder. Br. J. Psychiatry 2015, 10.1192/bjp.bp.115.163360.
10. Boufidou F., Nikolaou C., Alevizos B., Liappas I.A., Christodoulou G.N. Cytokine production in bipolar affective disorder patients under lithium treatment. J. Affect. Disord. 2004, 82:309-313.
11. Calkin C., van De Velde C., Ruzickova M., Slaney C., Garnham J., Hajek T., O'Donovan C., Alda M. Can body mass index help predict outcome in patients with bipolar disorder?. Bipolar Disord. 2009, 11:650-656.
12. Dickerson F., Stallings C., Origoni A., Vaughan C., Katsafanas E., Khushalani S., Yolken R. A combined marker of inflammation in individuals with mania. PloS One 2013, 8:e73520.
13. Dunn A.J., Swiergiel A.H., de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci. Biobehav. Rev. 2005, 29:891-909.
14. Fagiolini A., Frank E., Scott J.A., Turkin S., Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005, 7:424-430.
15. Fagiolini A., Kupfer D.J., Houck P.R., Novick D.M., Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am. J. Psychiatry 2003, 160:112-117.
16. Fain J.N. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm. 2010, 2010. 513948.
17. Fiedorowicz J.G., Palagummi N.M., Forman-Hoffman V.L., Miller D.D., Haynes W.G. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann. Clin. Psychiatry 2008, 20:131-137.
18. Goldstein B.I., Liu S.M., Zivkovic N., Schaffer A., Chien L.C., Blanco C. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011, 13:387-395.
19. Guh D.P., Zhang W., Bansback N., Amarsi Z., Birmingham C.L., Anis A.H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009, 9:88.
20. Haarman B.C., Riemersma-Van der Lek R.F., de Groot J.C., Ruhe H.G., Klein H.C., Zandstra T.E., Burger H., Schoevers R.A., de Vries E.F., Drexhage H.A., Nolen W.A., Doorduin J. Neuroinflammation in bipolar disorder - A [C]-(R)-PK11195 positron emission tomography study. Brain Behav. Immun. 2014, 40:219-225.
21. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. NEJM 2005, 352:1685-1695.
22. Hou R., Baldwin D.S. A neuroimmunological perspective on anxiety disorders. Hum. Psychopharmacol. 2012, 27:6-14.
23. Hung Y.J., Hsieh C.H., Chen Y.J., Pei D., Kuo S.W., Shen D.C., Sheu W.H., Chen Y.C. Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder. Clin. Endocrinol. 2007, 67:784-789.
24. Irwin M.R., Wang M., Campomayor C.O., Collado-Hidalgo A., Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch. Intern. Med. 2006, 166:1756-1762.
25. Kim Y.K., Jung H.G., Myint A.M., Kim H., Park S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007, 104:91-95.
26. Konner A.C., Bruning J.C. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol. Metab. 2011, 22:16-23.
27. Laursen T.M. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophrenia Res. 2011, 131:101-104.
28. McIntyre R.S., Alsuwaidan M., Goldstein B.I., Taylor V.H., Schaffer A., Beaulieu S., Kemp D.E. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann. Clin. Psychiatry 2012, 24:69-81.
29. Modabbernia A., Taslimi S., Brietzke E., Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol. Psychiatry 2013, 74:15-25.
30. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 2006, 90:263-267.
31. O'Donovan A., Rush G., Hoatam G., Hughes B.M., McCrohan A., Kelleher C., O'Farrelly C., Malone K.M. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress. Anxiety 2013, 30:307-314.
32. Padmos R.C., Hillegers M.H., Knijff E.M., Vonk R., Bouvy A., Staal F.J., de Ridder D., Kupka R.W., Nolen W.A., Drexhage H.A. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008, 65:395-407.
33. Prizment A.E., Anderson K.E., Visvanathan K., Folsom A.R. Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol. Biomarkers Prev. 2011, 20:297-307.
34. Rao J.S., Harry G.J., Rapoport S.I., Kim H.W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010, 15:384-392.
35. Rohleder N. Acute and chronic stress induced changes in sensitivity of peripheral inflammatory pathways to the signals of multiple stress systems. Psychoneuroendocrinology 2012, 37:307-316.
36. Schaffer A., McIntosh D., Goldstein B.I., Rector N.A., McIntyre R.S., Beaulieu S., Swinson R., Yatham L.N. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann. Clin. Psychiatry 2012, 24:6-22.
37. Sun S., Ji Y., Kersten S., Qi L. Mechanisms of inflammatory responses in obese adipose tissue. Annu. Rev. Nutr. 2012, 32:261-286.
38. Tehrani D.M., Gardin J.M., Yanez D., Hirsch C.H., Lloyd-Jones D.M., Stein P.K., Wong N.D. Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular health study. Atherosclerosis 2013, 231:246-251.
39. Tsai S.Y., Chung K.H., Wu J.Y., Kuo C.J., Lee H.C., Huang S.H. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J. Affect. Disord. 2012, 136:110-116.
40. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
41. Udina M., Hidalgo D., Navines R., Forns X., Sola R., Farre M., Capuron L., Vieta E., Martin-Santos R. Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J. Clin. Psychiatry 2014, 75:e1113-e1121.
42. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
43. Varadhan R., Yao W., Matteini A., Beamer B.A., Xue Q.L., Yang H., Manwani B., Reiner A., Jenny N., Parekh N., Fallin M.D., Newman A., Bandeen-Roche K., Tracy R., Ferrucci L., Walston J. Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults. J. Gerontol. A. Biol. Sci. Med. Sci. 2014, 69:165-173.
44. Wang P.W., Sachs G.S., Zarate C.A., Marangell L.B., Calabrese J.R., Goldberg J.F., Sagduyu K., Miyahara S., Ketter T.A. Overweight and obesity in bipolar disorders. J. Psychiatr. Res. 2006, 40:762-764.
45. Wang H.J., Zakhari S., Jung M.K. Alcohol, inflammation, and gut-liver-brain interactions in tissue damage and disease development. World J. Gastroenterol. 2010, 16:1304-1313.
46. Wurtz P., Wang Q., Kangas A.J., Richmond R.C., Skarp J., Tiainen M., Tynkkynen T., Soininen P., Havulinna A.S., Kaakinen M., Viikari J.S., Savolainen M.J., Kahonen M., Lehtimaki T., Mannisto S., Blankenberg S., Zeller T., Laitinen J., Pouta A., Mantyselka P., Vanhala M., Elliott P., Pietilainen K.H., Ripatti S., Salomaa V., Raitakari O.T., Jarvelin M.R., Smith G.D., Ala-Korpela M. Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS Med 2014, 11. e1001765.
47. Yao Y., Tsirka S.E. Monocyte chemoattractant protein-and the blood-brain barrier. Cell. Mol. Life Sci. 2014, 71:683-697.
48. Yatham L.N., Kauer-Sant'anna M., Bond D.J., Lam R.W., Tam E. Course and outcome after the first manic episode in patients with bipolar disorder: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM) project. Can. J. Psychiatry 2009, 54:105-112.
49. Yatham L.N., Kennedy S.H., Parikh S.V., Schaffer A., Beaulieu S., Alda M., O'Donovan C., Macqueen G., McIntyre R.S., Sharma V., Ravindran A., Young L.T., Milev R., Bond D.J., Frey B.N., Goldstein B.I., Lafer B., Birmaher B., Ha K., Nolen W.A., Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013, 15:1-44.